Target
PARP 1
2 abstracts
Abstract
Efficacy of olaparib combined to metronomic cyclophosphamide and metformin in patients with recurrent advanced/metastatic endometrial by molecular subtypes: ENDOLA phase I/II trial.Org: Gustave-Roussy Cancer Campus, Centre Antoine-Lacassagne, Pole Santé Publique, Pharmacie, URCC,
Abstract
Safety, pharmacokinetics and anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with locally advanced or metastatic solid tumors.Org: Jagiellonian University Hospital, Kraków, Poland, Kraków University Hospital, Krakow, Poland, Polish Mother's Memorial Hospital - Research Institute,